Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469418 | 1.00 | USP2 (0.45) | USP2SMN1; SMN2USP30SCD5CYP11B2 | |
| SCHEMBL2285992 | 1.00 | USP2 (0.45) | USP2SMN1; SMN2USP30SCD5CYP11B2 | |
| SCHEMBL6943029 | 0.90 | HPGD (0.43) | USP2SMN1; SMN2USP30SCD5CYP11B2 | |
| SCHEMBL20482260 | 0.90 | HPGD (0.43) | USP2SMN1; SMN2USP30SCD5CYP11B2 | |
| SCHEMBL2279068 | 0.90 | HPGD (0.43) | USP2SMN1; SMN2USP30SCD5CYP11B2 | |
| SCHEMBL225098 | 0.90 | USP2 (0.51) | USP2SMN1; SMN2HPGDEPHX2ALOX15 | |
| SCHEMBL22983787 | 0.89 | USP30 (0.42) | USP2SMN1; SMN2USP30SCD5CYP11B2 | |
| SCHEMBL22702488 | 0.87 | USP2 (0.45) | USP2SMN1; SMN2USP30SCD5CYP11B2 | |
| SCHEMBL13419535 | 0.86 | USP2 (0.46) | USP2SMN1; SMN2RORCHPGDEPHX2 | |
| SCHEMBL23582793 | 0.85 | USP2 (0.44) | USP2SMN1; SMN2USP30SCD5CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079960-A | Alkynyl quinazoline compounds | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4013749-B1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4594314-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | Azkarra Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| CN-119968364-A | Pyridazin-3 (2H) -one and pyridin-2 (1H) -one PARP inhibitor compounds | 阿兹卡拉疗法公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119390683-A | Alkynyl quinazoline compounds | 黑钻治疗公司 | 2025-02-07 | — | — | CN | disclosed |
| WO-2024073133-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | AZKARRA THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2023081328-A1 | HISTONE DEACETYLASE 6 INHIBITOR COMPOUNDS AND USES THEREOF | VALO HEALTH, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| EP-4013749-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | Black Diamond Therapeutics, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| US-8716483-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | USP2 3593/4885SMN1; SMN2 4291/4885USP30 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.